title: Overview of the use of Oncotype DX(®) as an additional treatment decision tool in early breast cancer.
abstract: Oncotype DX(®) is a multigene assay that provides prognostic information in terms of 10-year distant recurrence and predicts the likelihood of adjuvant chemotherapy benefit in estrogen receptor positive breast cancer patients, based on the expression of a panel of 21 genes (16 cancer-related and five reference genes) from a tumor specimen (core biopsy or surgical resection). It has been validated using multiple prospectively designed studies of archived tumor specimens from well-controlled clinical studies. In different countries with varying therapeutic approaches, using Oncotype DX has consistently resulted in a significant reduction in the number of patients who are prescribed chemotherapy, and in addition, it can identify a smaller subset of patients who would benefit from chemotherapy among patients who would otherwise receive endocrine therapy alone.
authors: Athens University Medical School, 8 Lassiou Street, 11521, Athens, Greece. cmarkop@hol.gr
authors: Christos
authors: C
authors: Markopoulos
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000601:surgery; D003362:Cost-Benefit Analysis; D005260:Female; D020869:Gene Expression Profiling / Q000191:economics / Q000379:methods*; D006801:Humans; D011237:Predictive Value of Tests; D011379:Prognosis; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism
chemical_list: D011960:Receptors, Estrogen